Nikos Pantazis

List of Publications by Citations

68 papers	2,363 citations	25 h-index	48 g-index
75 ext. papers	2,754 ext. citations	5.2 avg, IF	4.31 L-index

#	Paper	IF	Citations
68	Comparison of evidence of treatment effects in randomized and nonrandomized studies. *JAMA - Journal of the American Medical Association*, **2001**, 286, 821-30	27.4	567
67	Response to combination antiretroviral therapy: variation by age. *Aids*, **2008**, 22, 1463-73	3.5	173
66	Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds . *Clinical Infectious Diseases*, **2011**, 53, 817-25	11.6	155
65	Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection. *PLoS Pathogens*, **2016**, 12, e1005661	7.6	98
64	Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. *Lancet, The*, **2010**, 376, 340-5	40	77
63	Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts. *Clinical Infectious Diseases*, **2013**, 56, 888-97	11.6	76
62	Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. *Clinical Infectious Diseases*, **2018**, 66, 893-903	11.6	75
61	Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load. *Journal of Virology*, **2002**, 76, 10099-108	6.6	75
60	Frequency and distribution of root filled teeth and apical periodontitis in a Greek population. *International Endodontic Journal*, **2005**, 38, 105-11	5.4	73
59	Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. *American Journal of Epidemiology*, **2008**, 168, 532-40	3.8	71
58	Using CD4 Data to Estimate HIV Incidence, Prevalence, and Percent of Undiagnosed Infections in the United States. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2017**, 74, 3-9	3.1	69
57	High levels of postmigration HIV acquisition within nine European countries. *Aids*, **2017**, 31, 1979-1988	3.5	69
56	Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. *Aids*, **2009**, 23, 2029-37	3.5	54
55	Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2006**, 42, 554-61	3.1	54
54	Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates. *Aids*, **2004**, 18, 1697-705	3.5	48
53	The optimal home blood pressure monitoring schedule based on the Didima outcome study. *Journal of Human Hypertension*, **2010**, 24, 158-64	2.6	42
52	Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. *Lancet HIV,the*, **2015**, 2, e335-43	7.8	41

51	Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy. *Aids*, **2004**, 18, 2261-7	3.5	37
50	Multidrug-resistant and extensively drug-resistant Gram-negative prosthetic joint infections: Role of surgery and impact of colistin administration. *International Journal of Antimicrobial Agents*, **2019**, 53, 294-301	14.3	28
49	Factors associated with short-term changes in HIV viral load and CD4(+) cell count in antiretroviral-naive individuals. *Aids*, **2014**, 28, 1351-6	3.5	27
48	Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa. *PLoS ONE*, **2012**, 7, e32369	3.7	27
47	CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era. *Aids*, **2010**, 24, 2697-704	3.5	27
46	HIV-1 molecular transmission clusters in nine European countries and Canada: association with demographic and clinical factors. *BMC Medicine*, **2019**, 17, 4	11.4	27
45	Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV-1 positive patients with well-estimated dates of seroconversion. *HIV Medicine*, **2018**, 19, 184-194	2.7	27
44	Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort. *Aids*, **2007**, 21, 1283-91	3.5	25
43	Temporal trends in prognostic markers of HIV-1 virulence and transmissibility: an observational cohort study. *Lancet HIV,the*, **2014**, 1, e119-26	7.8	24
42	The effect of antiretroviral treatment of different durations in primary HIV infection. *Aids*, **2008**, 22, 2441-50	3.5	23
41	A randomized trial comparing concise and standard consent forms in the START trial. *PLoS ONE*, **2017**, 12, e0172607	3.7	22
40	Bivariate modelling of longitudinal measurements of two human immunodeficiency type 1 disease progression markers in the presence of informative drop-outs. *Journal of the Royal Statistical Society Series C: Applied Statistics*, **2005**, 54, 405-423	1.5	19
39	The influence of different power settings of Nd:YAG laser irradiation, bioglass and combination to the occlusion of dentinal tubules. *Photomedicine and Laser Surgery*, **2013**, 31, 54-8		18
38	Elevated serum levels of soluble immune activation markers are associated with increased risk for death in HAART-naive HIV-1-infected patients. *AIDS Patient Care and STDs*, **2003**, 17, 147-53	5.8	16
37	Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?. *Aids*, **2015**, 29, 2323-33	3.5	14
36	Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. *Clinical Infectious Diseases*, **2012**, 54, 111-8	11.6	14
35	Timing of combined antiretroviral treatment initiation in male and female migrants living with HIV in Western Europe. *Aids*, **2017**, 31, 835-846	3.5	11
34	Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE collaboration. *PLoS ONE*, **2013**, 8, e71174	3.7	11

33	Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients. *HIV Medicine*, **2017**, 18, 33-44	2.7	10
32	Rates and determinants of virologic and immunological response to HAART resumption after treatment interruption in HIV-1 clinical practice. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2008**, 49, 492-8	3.1	10
31	Changes in T cell receptor excision DNA circle (TREC) levels in HIV type 1-infected subjects pre- and post-highly active antiretroviral therapy. *AIDS Research and Human Retroviruses*, **2004**, 20, 47-54	1.6	9
30	Emergency care provided in a Greek dental school and analysis of the patients₂demographic characteristics: a prospective study. *International Dental Journal*, **2016**, 66, 280-6	2.2	9
29	HIV incidence in the Estonian population in 2013 determined using the HIV-1 limiting antigen avidity assay. *HIV Medicine*, **2018**, 19, 33-41	2.7	9
28	Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2017**, 76, 311-318	3.1	8
27	The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment. *Aids*, **2016**, 30, 879-88	3.5	8
26	Determining the likely place of HIV acquisition for migrants in Europe combining subject-specific information and biomarkers data. *Statistical Methods in Medical Research*, **2019**, 28, 1979-1997	2.3	8
25	Analyzing Longitudinal Data in the Presence of Informative Dropout: The Jmre1 Command. *The Stata Journal*, **2010**, 10, 226-251	3.5	7
24	Robustness of a parametric model for informatively censored bivariate longitudinal data under misspecification of its distributional assumptions: A simulation study. *Statistics in Medicine*, **2007**, 26, 5473-85	2.3	7
23	What do the changing patterns of comorbidity burden in people living with HIV mean for long-term management? Perspectives from European HIV cohorts. *HIV Medicine*, **2020**, 21 Suppl 2, 3-16	2.7	7
22	The permanent deformation of the self-adjusting files when used in canals of extracted teeth. *International Endodontic Journal*, **2013**, 46, 863-9	5.4	6
21	A Method to Estimate the Size and Characteristics of HIV-positive Populations Using an Individual-based Stochastic Simulation Model. *Epidemiology*, **2016**, 27, 247-56	3.1	5
20	Longitudinal and time-to-drop-out joint models can lead to seriously biased estimates when the drop-out mechanism is at random. *Biometrics*, **2019**, 75, 58-68	1.8	5
19	CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 2862-2868	5.1	4
18	Potential adjustment methodology for missing data and reporting delay in the HIV Surveillance System, European Union/European Economic Area, 2015. *Eurosurveillance*, **2018**, 23,	19.8	4
17	Ten-year survival outcomes of patients with potentially resectable gastric cancer: impact of clinicopathologic and treatment-related risk factors. *Annals of Gastroenterology*, **2019**, 32, 99-106	2.2	4
16	The carotico-clinoid bar: A systematic review and meta-analysis of its prevalence and potential implications in cerebrovascular and skull base surgery. *World Neurosurgery*, **2019**, 124, 267-267	2.1	3

#	Publication		
15	Birth order and memories of traumatic and family experiences in Greek patients with borderline personality disorder versus patients with other personality disorders. *Bulletin of the Menninger Clinic*, **2016**, 80, 234-54	1.3	3
14	Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?. *Clinical Infectious Diseases*, **2020**, 71, 2905-2916	11.6	3
13	Effect of incident hepatitis C infection on CD4+ cell count and HIV RNA trajectories based on a multinational HIV seroconversion cohort. *Aids*, **2019**, 33, 327-337	3.5	3
12	Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination.. *Vaccines*, **2022**, 10,	5.3	3
11	Effects of first antiretroviral regimen on lipid levels in HIV (+) individuals. *Journal of Chemotherapy*, **2012**, 24, 38-47	2.3	2
10	Preliminary Data of a Quantitative Point of Care Test for SARS-CoV-2 Antibodies From Greece. *In Vivo*, **2020**, 34, 3039-3045	2.3	2
9	Long-term evolution of CD4+ cell count in patients under combined antiretroviral therapy. *Aids*, **2019**, 33, 1645-1655	3.5	2
8	The HIV patient profile in 2013 and 2003: Results from the Greek AMACS cohort. *PLoS ONE*, **2018**, 13, e0203601	3.7	2
7	Treatment Modifications and Treatment-Limiting Toxicities or Side Effects: Risk Factors and Temporal Trends. *AIDS Research and Human Retroviruses*, **2015**, 31, 707-17	1.6	1
6	Performance of parametric survival models under non-random interval censoring: A simulation study. *Computational Statistics and Data Analysis*, **2013**, 63, 16-30	1.6	0
5	Disease progression and mortality with untreated HIV infection: evidence synthesis of HIV seroconverter cohorts, antiretroviral treatment clinical cohorts and population-based survey data. *Journal of the International AIDS Society*, **2021**, 24 Suppl 5, e25784	5.4	0
4	HIV continuum of care: expanding scope beyond a cross-sectional view to include time analysis: a systematic review. *BMC Public Health*, **2021**, 21, 1699	4.1	0
3	Discriminating Between Premigration and Postmigration HIV Acquisition Using Surveillance Data. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2021**, 88, 117-124	3.1	0
2	Misspecifying the covariance structure in a linear mixed model under MAR drop-out. *Statistics in Medicine*, **2020**, 39, 3027-3041	2.3	
1	Effectiveness of fissure sealants on initial caries lesions (ICDAS 1-3) of permanent molars: A 4-year follow-up. *European Journal of Paediatric Dentistry*, **2021**, 22, 180-188	1.1	